Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Direct Oral Anticoagulants for Treatment of Venous Thrombosis: Illustrated Review of Appropriate Use Publisher



Khairani CD1 ; Bejjani A1 ; Assi A1 ; Porio N1 ; Talasaz AH2, 3 ; Piazza G1, 4 ; Cushman M5 ; Bikdeli B1, 4, 6, 7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
  2. 2. Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
  5. 5. Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, United States
  6. 6. Yale New Haven Hospital/Yale Center for Outcomes Research and Evaluation (CORE), New Haven, CT, United States
  7. 7. Cardiovascular Research Foundation (CRF), New York, NY, United States

Source: Research and Practice in Thrombosis and Haemostasis Published:2024


Abstract

Direct oral anticoagulants (DOACs) have become the preferred option for treatment of venous thromboembolism due to their favorable profile compared with other agents such as vitamin K antagonists or low-molecular-weight heparin. However, findings from randomized controlled trials suggest efficacy and/or safety concerns with DOAC use in some clinical contexts. This illustrated review will summarize indications where DOACs have proven efficacy and safety, situations where they fall short, and situations where uncertainty remains compared with other treatments for venous thromboembolism. © 2024 The Author(s)